June 17, 2025
PRESS RELEASE 12 June 2025 On 7 May 2025, the FDA approved an IND application enabling Myrio’s lead product (PHOX2B PC-CAR T) to enter human trials. […]
June 6, 2025
6th June, 2025 Key Highlights Myrio Tx and University of Pennsylvania’s long standing collaboration has yielded compelling results in developing first-in-class and best-in-class next-generation cancer therapies […]
April 15, 2025
March 14, 2025
The Myrio team recently participated in the Spring edition of the Society for Immunotherapy of Cancer (SITC), where Matt Beasley (Co-founder, CSO) and Dr. Lauren Pitt (Head of Preclinical) presented at […]
November 12, 2024
Psaio Therapeutics (subsidery of Myrio Therapeutics) is thrilled to announce that it has been selected as a finalist in the 2024 ANZ Advance Biotech Grant Program […]